Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GI-4000 + bevacizumab
- Development stage
- Preclinical
- Lead developer
- ImmunityBio
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
GI-4000 + bevacizumab is an investigational combination therapy for cancer, primarily studied in colorectal and pancreatic cancers. GI-4000 is a therapeutic cancer vaccine platform consisting of recombinant yeast expressing mutated RAS proteins, designed to elicit an immune response against tumors harboring specific KRAS mutations. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and tumor blood supply. The combination aims to leverage the immunogenic effects of the vaccine with the antiangiogenic properties of bevacizumab to improve antitumor efficacy[3][4][6].
02
Targets
MHC I (MHC class I})VEGFA (Vascular endothelial growth factor A)KRAS G12D/G12V pMHC-I (KRAS G12D/G12V peptide–MHC class I complex)
Beyond the preview
Go deeper on GI-4000 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GI-4000 + bevacizumab.